The Joint Corp. Q2 system-wide sales +13% to $120.1M; financial results postponed due to review

JOINT Corp

2023-Q2 EPS reported $0.13 revenue$57,608,005

System-wide sales $120.1M (+13% YoY); system-wide comp sales +5%.
Clinic count 890 at June 30; subsequent openings brought total to 900 in August 2023.
Unrestricted cash $13.6M (Dec 2022: $9.7M); operating cash flow $8.4M including $4.8M ERC.
Financial results postponed due to ongoing review of regional developer arrangements (non-cash impact).
Sold 21 franchise licenses in Q2; opened 26 new clinics, closed 6.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

JOINT Corp reported preliminary financial results for the quarter ended June 30, 2023.

Period: the quarter ended June 30, 2023
Result: preliminary results

Exact text from the filing

The Joint Corp. (the “Company”) issued a press release announcing its preliminary financial results for the quarter ended June 30, 2023.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

JOINT Corp filing history →

Source: SEC EDGAR

accession 0001171843-23-005230

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.